{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:39:14Z","timestamp":1758587954084,"version":"3.44.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"DOI":"10.7759\/cureus.92947","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:23:08Z","timestamp":1758565388000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum Oxysterol Levels in Heart Failure With Preserved Ejection Fraction: A Prospective Case-Control Study"],"prefix":"10.7759","author":[{"given":"Musa","family":"Dagli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Kerk\u00fctl\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Alkan Baylan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Gunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022, 79:e263-421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske B","year":"2019","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, et al.. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019, 40:3297-317. 10.1093\/eurheartj\/ehz641","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug BA","year":"2011","unstructured":"Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011, 32:670-9. 10.1093\/eurheartj\/ehq426","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield MM","year":"2003","unstructured":"Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003, 289:194-202. 10.1001\/jama.289.2.194","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.716886","article-title":"Role of left ventricular stiffness in heart failure with normal ejection fraction","volume":"117","author":"Westermann D","year":"2008","unstructured":"Westermann D, Kasner M, Steendijk P, et al.. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008, 117:2051-60. 10.1161\/CIRCULATIONAHA.107.716886","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000155257.33485.6D","article-title":"Cardiomyocyte stiffness in diastolic heart failure","volume":"111","author":"Borb\u00e9ly A","year":"2005","unstructured":"Borb\u00e9ly A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005, 111:774-81. 10.1161\/01.CIR.0000155257.33485.6D","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1201","article-title":"Progression of left ventricular diastolic dysfunction and risk of heart failure","volume":"306","author":"Kane GC","year":"2011","unstructured":"Kane GC, Karon BL, Mahoney DW, et al.. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011, 306:856-63. 10.1001\/jama.2011.1201","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16388","article-title":"Do oxysterols control cholesterol homeostasis?","volume":"110","author":"Bj\u00f6rkhem I","year":"2002","unstructured":"Bj\u00f6rkhem I. Do oxysterols control cholesterol homeostasis?. J Clin Invest. 2002, 110:725-30. 10.1172\/JCI16388","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(98)00196-8","article-title":"Oxysterols and atherosclerosis","volume":"142","author":"Brown AJ","year":"1999","unstructured":"Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 1999, 142:1-28. 10.1016\/s0021-9150(98)00196-8","journal-title":"Atherosclerosis"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-2275(20)41115-0","article-title":"Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL","volume":"36","author":"Sevanian A","year":"1995","unstructured":"Sevanian A, Hodis HN, Hwang J, McLeod LL, Peterson H. Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL. J Lipid Res. 1995, 36:1971-86.","journal-title":"J Lipid Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.16.9681","article-title":"Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms","volume":"273","author":"Harada-Shiba M","year":"1998","unstructured":"Harada-Shiba M, Kinoshita M, Kamido H, Shimokado K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem. 1998, 273:9681-7. 10.1074\/jbc.273.16.9681","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nm820","article-title":"Reciprocal regulation of inflammation and lipid metabolism by liver X receptors","volume":"9","author":"Joseph SB","year":"2003","unstructured":"Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003, 9:213-9. 10.1038\/nm820","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M601019200","article-title":"24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux","volume":"281","author":"Abildayeva K","year":"2006","unstructured":"Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, et al.. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem. 2006, 281:12799-808. 10.1074\/jbc.M601019200","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0926-6917(92)90020-d","article-title":"Effects of cholesterol and oxysterols on gap junctional communication between human smooth muscle cells","volume":"228","author":"Zwijsen RM","year":"1992","unstructured":"Zwijsen RM, Oudenhoven IM, de Haan LH. Effects of cholesterol and oxysterols on gap junctional communication between human smooth muscle cells. Eur J Pharmacol. 1992, 228:115-20. 10.1016\/0926-6917(92)90020-d","journal-title":"Eur J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus WJ","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013, 62:263-71. 10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah SJ","year":"2016","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016, 134:73-90. 10.1161\/CIRCULATIONAHA.116.021884","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0097-6","article-title":"The role of adipose tissue in cardiovascular health and disease","volume":"16","author":"Oikonomou EK","year":"2019","unstructured":"Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. 2019, 16:83-99. 10.1038\/s41569-018-0097-6","journal-title":"Nat Rev Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92035","article-title":"Inflammatory mechanisms linking obesity and metabolic disease","volume":"127","author":"Saltiel AR","year":"2017","unstructured":"Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017, 127:1-4. 10.1172\/JCI92035","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.1999.00575.x","article-title":"Ca2+ sparks and Ca2+ waves in saponin-permeabilized rat ventricular myocytes","volume":"521","author":"Lukyanenko V","year":"1999","unstructured":"Lukyanenko V, Gyorke S. Ca2+ sparks and Ca2+ waves in saponin-permeabilized rat ventricular myocytes. J Physiol. 1999, 521:575-85. 10.1111\/j.1469-7793.1999.00575.x","journal-title":"J Physiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s1050-1738(01)00106-2","article-title":"Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols","volume":"11","author":"Colles SM","year":"2001","unstructured":"Colles SM, Maxson JM, Carlson SG, Chisolm GM. Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. Trends Cardiovasc Med. 2001, 11:131-8. 10.1016\/s1050-1738(01)00106-2","journal-title":"Trends Cardiovasc Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"7","author":"Shah AM","year":"2014","unstructured":"Shah AM, Claggett B, Sweitzer NK, et al.. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circ Heart Fail. 2014, 7:740-51. 10.1161\/CIRCHEARTFAILURE.114.001583","journal-title":"Circ Heart Fail"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000854","article-title":"Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction","volume":"7","author":"Burke MA","year":"2014","unstructured":"Burke MA, Katz DH, Beussink L, et al.. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014, 7:288-99. 10.1161\/CIRCHEARTFAILURE.113.000854","journal-title":"Circ Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2012.123","article-title":"The many faces of heart failure with preserved ejection fraction","volume":"9","author":"Shah AM","year":"2012","unstructured":"Shah AM, Pfeffer MA. The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2012, 9:555-6. 10.1038\/nrcardio.2012.123","journal-title":"Nat Rev Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-1981(00)00142-6","article-title":"Oxysterol biosynthetic enzymes","volume":"1529","author":"Russell DW","year":"2000","unstructured":"Russell DW. Oxysterol biosynthetic enzymes. Biochim Biophys Acta. 2000, 1529:126-35. 10.1016\/s1388-1981(00)00142-6","journal-title":"Biochim Biophys Acta"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406540-serum-oxysterol-levels-in-heart-failure-with-preserved-ejection-fraction-a-prospective-case-control-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:23:09Z","timestamp":1758565389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406540-serum-oxysterol-levels-in-heart-failure-with-preserved-ejection-fraction-a-prospective-case-control-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.92947","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}